卵巢癌术前血浆纤维蛋白原水平与化疗效应的相关性研究  

Correlation between Preoperative Plasma Fibrinogen Level and Chemotherapy Effect in Ovarian Cancer Patients

作　　者：谢科宇[1] 谢先丰[1] Xie Keyu Xie Xianfeng(Chengdu Second People＇s Hospital, Chengdu 610000, China)

机构地区：[1]成都市第二人民医院,成都610000

出　　处：《中国药师》2017年第9期1593-1595,共3页China Pharmacist

摘　　要：目的:探讨卵巢癌患者的纤维蛋白原水平与铂类药物化疗方案治疗效应的相关性。方法:纳入91例卵巢癌患者和同期95例良性卵巢肿瘤患者,分析术前血浆纤维蛋白原水平和临床病理参数以及患者化疗效应的关联。结果:36.26%(33/91)的卵巢癌患者呈现高纤维蛋白原水平(>4.0 g·L^(-1))。卵巢癌患者纤维蛋白原水平升高与卵巢癌(FIGO)分期存在显著相关性(P<0.05),但与年龄、病理学级别不相关(P>0.05)。患者发生高纤维蛋白原血症与血清肿瘤抗原CA125水平升高并不存在相关性(P>0.05)。高纤维蛋白原血症的患者出现化疗耐药的比例显著高于正常水平患者(P<0.05),高纤维蛋白原水平的OR值为3.571,95%CI为1.276~10.000,提示高纤维蛋白原水平是化疗抵抗的危险因素。结论:本研究表明,卵巢癌患者呈现高纤维蛋白原水平可能预示着铂类药物化疗反应差,是一个与血清CA-125不相关的潜在预后因素。Objective： To explore the correlation between fibrinogen levels and chemotherapy effect of platinum drugs in ovarian cancer patients. Methods： Totally 91 ovarian cancer patients and 95 patients with benign ovarian tumor were involved in our retrospective study, and the associations between preoperative fibrinogen levels and clinic pathologic parameters in the patients were analyzed. Results： High fibrinogen levels were observed in 36.26% （33/91） of the patients with ovarian cancer （ 〉4.0 g · L^-1 ）, which was significantly higher than that in the patients with benign tumor（P 〈 0.05）. The high fibrinogen levels in ovarian cancer patients were associated with the higher FIGO stage and poor chemo-response, while were not associated with the patients＇ age, CA-125 levels and histological type and grade （P 〉0.05）. More importantly, no correlation was observed between high blood fibrinogen and CA-125 levels （P 〉 0.05 ）. Chemotherapy resistance was more in the patients with high fibrinogen levels than that in the other patients （ P 〈 0.05）. The OR value of high fibrinogen levels was 3. 571, 95% CI was 1. 276-10.000, which suggested high fibrinogen level is a dangerous factor for chemotherapy resistance. Conclusion： The study suggested that elevated fibriuogen level was a dangerous factor for chemotherapy response, which has a potential role in the poor prognosis of ovarian cancer patients independent of CA-125.

关 键 词：纤维蛋白原 卵巢癌 化疗效应 

分 类 号：R737.31[医药卫生—肿瘤]